1. Home
  2. LEXX vs PCLA Comparison

LEXX vs PCLA Comparison

Compare LEXX & PCLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LEXX
  • PCLA
  • Stock Information
  • Founded
  • LEXX 2004
  • PCLA 2008
  • Country
  • LEXX Canada
  • PCLA Japan
  • Employees
  • LEXX N/A
  • PCLA N/A
  • Industry
  • LEXX Biotechnology: Pharmaceutical Preparations
  • PCLA Building Products
  • Sector
  • LEXX Health Care
  • PCLA Consumer Discretionary
  • Exchange
  • LEXX Nasdaq
  • PCLA Nasdaq
  • Market Cap
  • LEXX 16.5M
  • PCLA 14.2M
  • IPO Year
  • LEXX N/A
  • PCLA 2025
  • Fundamental
  • Price
  • LEXX $1.03
  • PCLA $0.44
  • Analyst Decision
  • LEXX Strong Buy
  • PCLA
  • Analyst Count
  • LEXX 1
  • PCLA 0
  • Target Price
  • LEXX $4.00
  • PCLA N/A
  • AVG Volume (30 Days)
  • LEXX 187.7K
  • PCLA 200.0K
  • Earning Date
  • LEXX 07-14-2025
  • PCLA 01-01-0001
  • Dividend Yield
  • LEXX N/A
  • PCLA N/A
  • EPS Growth
  • LEXX N/A
  • PCLA N/A
  • EPS
  • LEXX N/A
  • PCLA N/A
  • Revenue
  • LEXX $615,923.00
  • PCLA $5,475,228.00
  • Revenue This Year
  • LEXX $46.98
  • PCLA N/A
  • Revenue Next Year
  • LEXX $17.26
  • PCLA N/A
  • P/E Ratio
  • LEXX N/A
  • PCLA N/A
  • Revenue Growth
  • LEXX 49.85
  • PCLA 40.19
  • 52 Week Low
  • LEXX $0.77
  • PCLA $0.37
  • 52 Week High
  • LEXX $3.72
  • PCLA $9.80
  • Technical
  • Relative Strength Index (RSI)
  • LEXX 63.07
  • PCLA 38.66
  • Support Level
  • LEXX $0.86
  • PCLA $0.43
  • Resistance Level
  • LEXX $1.09
  • PCLA $0.53
  • Average True Range (ATR)
  • LEXX 0.08
  • PCLA 0.04
  • MACD
  • LEXX 0.02
  • PCLA 0.03
  • Stochastic Oscillator
  • LEXX 81.47
  • PCLA 8.59

About LEXX Lexaria Bioscience Corp.

Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.

About PCLA PicoCELA Inc. American Depositary Shares

PicoCELA Inc specializes in manufacturing, installing, and servicing enterprise wireless mesh solutions. The company generates revenue from two main sources: product equipment sales, and Software as a Service (SaaS) and maintenance services. The company develops the PCWL series of mesh Wi-Fi access points, which utilize its proprietary PicoCELA Backhaul Engine (PBE) technology to enable wireless communication. The company outsources manufacturing and sells these devices directly to customers through distributors. Additionally, the company offers a cloud portal service in a SaaS model, allowing users to monitor connectivity and traffic at their access points. This platform also supports the installation of proprietary edge-computing software into the devices.

Share on Social Networks: